Biology Reference
In-Depth Information
Saini, N., and Schaffner, W. (2010). Zinc supplement greatly improves the condition of parkin
mutant Drosophila. Biol. Chem. 391, 513-518.
Saini, N., Oelhafen, S., Hua, H., Georgiev, O., Schaffner, W., and Bueler, H. (2010). Extended
lifespan of Drosophila parkin mutants through sequestration of redox-active metals enhancement
of anti-oxidative pathways. Neurobiol. Dis. 40(1), 82-92.
Samaranch, L., Lorenzo-Betancor, O., Arbelo, J. M., Ferrer, I., Lorenzo, E., Irigoyen, J., Pastor, M. A.,
Marrero, C., Isla, C., Herrera-Henriquez, J., et al. (2010). PINK1-linked parkinsonism is associated
with Lewy body pathology. Brain 133, 1128-1142.
Sang, T. K., Chang, H. Y., Lawless, G. M., Ratnaparkhi, A., Mee, L., Ackerson, L. C.,
Maidment, N. T., Krantz, D. E., and Jackson, G. R. (2007). A Drosophila model of mutant
human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and depen-
dence on cellular dopamine.
J. Neurosci. 27, 981-992.
Sarov, M., and Stewart, A. F. (2005). The best control for the specificity of RNAi.
Trends Biotechnol.
23, 446-448.
Sayre, L. M., Perry, G., and Smith, M. A. (2008). Oxidative stress and neurotoxicity.
Chem. Res.
Toxicol. 21, 172-188.
Scherzer, C. R., Jensen, R. V., Gullans, S. R., and Feany, M. B. (2003). Gene expression changes
presage neurodegeneration in a Drosophila model of Parkinson's disease.
Hum. Mol. Genet. 12,
2457-2466.
Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J. F., and Morelli, M. (2006). Targeting adenosine
A2A receptors in Parkinson's disease.
Trends Neurosci. 29, 647-654.
Shulman, J. M., and Feany, M. B. (2003). Genetic modifiers of tauopathy in Drosophila.
Genetics
165, 1233-1242.
Silvestri, L., Caputo, V., Bellacchio, E., Atorino, L., Dallapiccola, B., Valente, E. M., and Casari, G.
(2005). Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive
parkinsonism.
Hum. Mol. Genet. 14, 3477-3492.
Simon-Sanchez, J., and Singleton, A. B. (2008). Sequencing analysis of OMI/HTRA2 shows
previously reported pathogenic mutations in neurologically normal controls. Hum. Mol. Genet.
17, 1988-1993.
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997).
Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
St Johnston, D. (2002). The art and design of genetic screens: Drosophila melanogaster. Nat. Rev. 3,
176-188.
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A.,
Schmidt, E., Zhu, Y. Z., Greenwald, M., et al. (2001). Histone deacetylase inhibitors arrest
polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743.
Steinbrink, S., and Boutros, M. (2008). RNAi screening in cultured Drosophila cells. Methods Mol.
Biol. 420, 139-153.
Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., Gasser, T.,
Wszolek, Z., Muller, T., Bornemann, A.,
et al
. (2005). Loss of function mutations in the gene
Hum. Mol. Genet. 14, 2099-2111.
Sutovsky, P., Moreno, R. D., Ramalho-Santos, J., Dominko, T., Simerly, C., and Schatten, G. (1999).
Ubiquitin tag for sperm mitochondria.
encoding Omi/HtrA2 in Parkinson's disease.
Nature 402, 371-372.
Tain, L. S., Chowdhury, R. B., Tao, R. N., Plun-Favreau, H., Moisoi, N., Martins, L. M.,
Downward, J., Whitworth, A. J., and Tapon, N. (2009a). Drosophila HtrA2 is dispensable for
apoptosis but acts downstream of PINK1 independently from Parkin.
Cell Death Differ. 16(8),
1118-1125.
Tain, L. S., Mortiboys, H., Tao, R. N., Ziviani, E., Bandmann, O., and Whitworth, A. J. (2009b).
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.
Nat. Neurosci.
12, 1129-1135.
